Trials Sponsors Conditions Drugs Pricing

Conditions

Psychotic Disorders Schizoaffective Disorder Schizophrenia

Outcome Measures

Primary Outcomes (1)

PANSS (The Positive And Negative Syndrome Scale) in a 12 week period

Secondary Outcomes (1)

CGI-C score (Clinical Global Impression of Change), UKU-SERS-Pa (Patient self rating version). Safety and tolerability: ECG, serum cholesterol, triglycerides, prolactin, glucose and body weight

Interventions

ziprasidone versus olanzapine , risperidone or quetiapineDrug

Panss , CGI-C, UKU-SERS-PaBehavioral

Blood testsProcedure

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
ziprasidone versus olanzapine , risperidone or quetiapine
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator

Sponsors & Collaborators

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industrylead

Study Sites (43)

Pfizer Investigational Site

Aalborg, 9100, Denmark

Pfizer Investigational Site

Arhus C, 8000, Denmark

Pfizer Investigational Site

Augustenborg, 6440, Denmark

Pfizer Investigational Site

Ballerup Municipality, 2750, Denmark

Pfizer Investigational Site

Brovst, 9460, Denmark

Pfizer Investigational Site

Copenhagen, 2100, Denmark

Pfizer Investigational Site

Dianalund, 4293, Denmark

MeSH Terms

Conditions

SchizophreniaPsychotic Disorders

Interventions

RisperidoneQuetiapine FumarateHematologic Tests

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PyrimidinonesPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsDibenzothiazepines

Study Officials

Pfizer CT.gov Call Center
Pfizer
STUDY DIRECTOR

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 8, 2005

First Posted

September 12, 2005

Study Start

November 2001

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

September 2004

Date type not reported

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (43)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (43)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations